The hypothesis that penicillin acts as an active-site inhibitor of cell wall biosynthesis was tested by a method of partial proteolytic mapping of penicillin (6, 9, 14) . This was possible because of a rate of acceleration of the acylation step relative to the deacylation step, giving an increase in the steady-state concentration of the covalent intermediate. Thus, these 14C-labeled substrates can be used to specifically label the active site of D-alanine carboxypeptidases from a variety of bacteria.
Penicillin kills susceptible bacteria by specifically inhibiting the transpeptidase(s) and D-alanine carboxypeptidase(s) that catalyze the final cross-linking step in cell wall peptidoglycan biosynthesis (15) . However, there has been disagreement on the chemical details of this inhibition. Although it is known that penicillin and related ,B-lactam antibiotics bind covalently to a defined set of membrane-bound and exocellular bacterial proteins, including the cell wall carboxypeptidases and transpeptidases, it has been suggested that penicillins bind at an active site (i.e., the substrate-binding site) or, alternatively, at an allosteric site (4, 11) . In the case of Dalanine carboxypeptidases from Bacillus stearothermophilus (14) and Bacillus subtilis (12) , it was recently shown that penicillin acylates the active-site serine. However, evidence in support of the allosteric model was accumulated from studies of D-alanine carboxypeptidases from several Streptomyces strains (4) , raising the possibility that the mechanism of penicillin inhibition is different in different bacteria or with other enzymes. Rigorous proof that penicillin binds covalently to the active site of sensitive enzymes from Bacillus spp. required a large amount of purified protein for the isolation of active-site peptides and the determination of their amino acid sequences. Thus, it was desirable to develop a method that required only small amounts of the enzymes in question and that would facilitate a relatively rapid analysis to determine whether penicillin is bound at the substrate-binding site. This paper describes such a method and its application to penicillin-binding proteins (PBP) (all D-alanine carboxypeptidases) from Streptomyces R61, Escherichia coli, and Staphylococcus aureus, as well as the application of the method to the D-alanine carboxypeptidases from Bacillus spp. studied previously (12, 14) .
Most of the PBP that have been isolated as active enzymes have D-alanine carboxypeptidase activity; i.e., they catalyze the removal of the terminal D-alanine from natural and cell wallrelated substrates such as UDP-N-acetylmura- (6, 9, 14) . This was possible because of a rate of acceleration of the acylation step relative to the deacylation step, giving an increase in the steady-state concentration of the covalent intermediate. Thus, these 14C-labeled substrates can be used to specifically label the active site of D-alanine carboxypeptidases from a variety of bacteria.
In this study, an enzyme labeled with
Ac2-lys-ala-lac), which will be referred to here- The method was then applied to purified PBP from other bacteria. Of special interest was the Streptomyces R61 exocellular D-alanine carboxypeptidase, whose kinetic and spectral properties had been interpreted as suggesting that the penicillin-and substrate-binding sites were different. Labeling of the Streptomyces R61 enzyme with [14C]penicillin G and [14C]Ac2-lysala-lac, followed by partial proteolysis and gel electrophoresis, showed indistinguishable patterns of labeled peptides (Fig. 2) . Thus, penicillin is an active-site inhibitor for the streptomyces R61 enzyme, in contradiction with the conclusion of Ghuysen et al. (4) .
Membranes of E. coli contain at least seven PBP, several of which have been purified. Two, designated PBP 5 and 6, have recently been shown to have D-alanine carboxypeptidase activity (1 [14C]Ac2-lys-ala-lac gave identical maps when three different methods of cleavage were used (Fig. 3) . Incidentally, an adaptation of this technique has been used to demonstrate that PBP 5 and 6 contain primary structures distinct from each other, making it unlikely that PBP 6 is a proteolytic derivative of PBP 5 (1) .
Although most recent studies on the mode of action of penicillin have focused on Streptomyces, Bacillus spp., and E. coli, many of the early studies on the modes of action of 1-lactam antibiotics used Staphylococcus aureus as a model organism (11, 13 transpeptidase and weak penicillinase activity (6) . It can be covalently labeled with [14C]penicillin G or [14C]AC2-lys-ala-lac, so it too was subjected to active site mapping (Fig. 4) . In this case, peptides generated from the [14C]penicillin G-labeled enzyme gave a pattern similar but not identical to that of peptides derived from the [14C]Ac2-lys-ala-lac-labeled enzyme in the case of cleavages with CNBr (Fig. 4, lanes 2, 3, 9 , and 10) and chymotrypsin (Fig. 4, lanes 4, 5, 11 , and 12). The [14C]penicillin G peptides appeared to be a subset of the 14C-substrate-labeled peptides; i.e., several additional labeled bands were present in the latter case. In the case of cleavage with staphylococcal protease (Fig. 4, lanes 6 bacteria studied in the present experiment (including both gram-negative and gram-positive organisms) appear to be identical in this respect, it is probable that this mechanism of action of penicillin will be true for many enzymes that bind penicillin covalently. The studies presented here and elsewhere (1, 4, 12, 14) have focused on the lower-molecular-weight cell wall carboxypeptidases because they can be purified in active form. Until very recently, the higher-molecularweight transpeptidases have been refractory to similar studies because they appear to be present in minute amounts in bacterial membranes and because they lose activity upon purification. However, the putative E. coli transpeptidases, PBP 1A and lBs have recently been cloned, overproduced, and purified in partially active form (5, 8, 10) . The method described in this paper should be useful in examining the generality of the hypothesis that penicillin acts as an active-site inhibitor of these cell wall transpeptidases.
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